New hope for Hard-to-Treat breast cancer: experimental drug CLR 125 enters human testing
Disease control
Recruiting now
This early-phase study is testing an experimental drug called CLR 125 in 60 people with advanced triple-negative breast cancer that has not responded to prior treatments. The main goals are to find the safest and most effective dose and to understand what side effects occur. Part…
Phase: PHASE1 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC